Neurocrine Biosciences Inc (NBIX)

Add to Watchlists
Create an Alert
Quickflows
93.90 -1.87  -1.95% NASDAQ Jul 27, 14:38 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All NBIX News

News

View All Events

Events

Date Type Description
08/03/2021 Earnings Results Q2 2021 Earnings Results
08/03/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
05/19/2021 10:30 EST AGM 2020 Annual General Meeting
05/05/2021 Earnings Results Q1 2021 Earnings Results
05/05/2021 16:30 EST Earnings Calls Q1 2021 Earnings Call
02/04/2021 Earnings Results Q4 2020 Earnings Results
02/04/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
11/09/2020 Earnings Results Q3 2020 Earnings Results
11/09/2020 16:30 EST Earnings Calls Q3 2020 Earnings Call
08/03/2020 16:30 EST Earnings Calls Q2 2020 Earnings Call
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.045B
Total Expenses (TTM) 745.30M
Net Income (TTM) 402.00M

Balance Sheet View Statement

Total Assets (Quarterly) 1.846B
Total Liabilities (Quarterly) 640.80M
Shareholders Equity (Quarterly) 1.206B

Cash Flow Statement View Statement

Cash from Operations (TTM) 280.30M
Cash from Investing (TTM) 34.00M
Cash from Financing (TTM) -148.70M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
  • URL: http://www.neurocrine.com
  • Investor Relations URL: https://www.neurocrine.com/about-us/webcasts-presentations
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 03, 2021
  • Last Earnings Release: May. 05, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Dec. 29, 1995

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 93.90
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.34%
PBE Invesco Dynamic Biotech & Genome ETF 2.76%
ETCHX Eventide Healthcare & Life Sciences C 2.09%
JCNIX Janus Henderson Contrarian S 1.97%
FIJYX Fidelity Advisor® Biotechnology Z 1.94%
BBH VanEck Vectors Biotech ETF 1.84%
JFNSX Janus Henderson Global Life Sciences S 1.75%
GTMRX Goldman Sachs Small/Mid Cap Growth R 1.38%
HQH Tekla Healthcare Investors 1.23%
JGMCX Janus Henderson Triton C 1.03%
IJK iShares S&P Mid-Cap 400 Growth ETF 0.85%
MDYG SPDR® S&P 400 Mid Cap Growth ETF 0.83%

Comparables

Edit
CRIS Curis Inc
NVAX Novavax Inc
SGEN Seagen Inc
BSX Boston Scientific Corp
AIM AIM ImmunoTech Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.